Phaseline

Targets › PIK3CG

PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform): drug programs, companies and trials

8 programs from 8 companies in 34 trials: 16 Phase 1, 15 Phase 2, 3 Phase 3; Oncology, Infectious disease, Other; next expected readout Dec 2026.

Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. (UniProt, P48736)

Open in Phaseline: the race on PIK3CG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CelcuityGedatolisib
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 3Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast CancerDec 2026
SecuraBioDuvelisib
PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor
PIK3CD, PIK3CGPhase 3Lymphoma; Newly Diagnosed Peripheral T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia …Feb 2028
Rhizen PharmaceuticalsTenalisib (RP6530)
PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor
PIK3CD, PIK3CGPhase 2Triple Negative Breast Cancer (TNBC)Dec 2026
National Cancer Institute (NCI)Taselisib (GDC-0032)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 2Advanced LymphomaMar 2027
RestorbioDactolisib (BEZ235)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 2Respiratory Tract Infections; Covid19–
Eli LillySamotolisib (LY3023414)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 1Breast Neoplasms; Endometrial CancerDec 2026
SovargenPaxalisib (SVG103)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 1Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation …Feb 2027
Stelexis BioSciencesEganelisib
PI3-kinase p110-gamma subunit inhibitor
PIK3CGPhase 1AML, Adult; Leukemia, MyeloidDec 2027

Conditions

Breast Cancer (2) Endometrial Cancer (2) Respiratory Tract Infections (1) Covid19 (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1) TNBC - Triple-Negative Breast Cancer (1) Advanced Lymphoma (1) Breast Neoplasms (1) Triple Negative Breast Cancer (TNBC) (1) Focal Cortical Dysplasia (1) Primary Central Nervous System Lymphoma (1) Glioblastoma (1)

Modalities

small molecule (7), mixed (1)

Companies

Restorbio (1) Celcuity (1) National Cancer Institute (NCI) (1) Eli Lilly (1) Rhizen Pharmaceuticals (1) Sovargen (1) SecuraBio (1) Stelexis BioSciences (1)

Related targets

PIK3R1 (5) PIK3CB (5) PIK3CA (5) MTOR (3) PIK3R2 (2) PIK3CD (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.